[1] Fjällskog ML, Granberg DP, Welin SL, et al.Treatment with cisplatin and etoposide in patients with neuroendocrine tumors[J].Cancer,2001,92(5):1101-1107.
[2] Modlin IM,Lye KD,Kidd M.A 5-decade analysis of 13,715 carcinoid tumors[J].Cancer,2003,97(4): 934-959.
[3] 曾杨,何晓生,何小生,等.胃低分化神经内分泌癌一例[J].中华普通外科学文献(电子版),2011,5(2):148-149.
[4] Ishida M,Sekine S,Fukagawa T,et al.Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis[J].Am J Surg Pathol,2013,37(7):949-959.
[5] Namikawa T,Oki T,Kitagawa H,et al.Neuroendocrine carcinoma of the stomach:clinicopathological and immunohistochemical evaluation[J].Med Mol Morphol,2013,46(1): 34-40.
[6] 杨晓鸥,李景南,钱家鸣,等.血浆嗜铬粒蛋白A对多种神经内分泌肿瘤的诊断价值[J].中华内科杂志,2011,50(2):124-127.
[7] Kanakis G, Kaltsas G.Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)[J].Best Pract Res Clin Gastroenterol,2012,26(6):791-802.
[8] 董兰花,沈虹,潘文胜.消化道神经内分泌癌生长模式的探讨[J].实用肿瘤杂志,2008,23(2):121-125.
[9] 汪慧访,武爱文,袁鹏,等.具有神经内分泌特征胃癌的诊治及预后分析[J].中华胃肠外科杂志,2011,14(2):96-99.
[10] 陶曙,桂林,蒋鹏程.27例胃神经内分泌肿瘤的诊疗分析[J].中国现代普通外科进展,2015,18(10):815-817.
[11] Grande E,Díez JJ,Pachón V,et al.Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)[J].Clin Transl Oncol,2010,12(7):481-492.
[12] Kirii Y, Ichikawa C, Miyamoto M, et a1. A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-ll proved very effective[J].Gan To Kagaku Ryoho,2010,37(5):895-898.
[13] Ohhinata R,Iwasaki Y,Ohashi M,et a1.A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP[J].Gan To Kagaku Ryoho,2010,37(12):2508-2510.
[14] Ramage JK,Ahmed A,Ardill J,et al.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)[J].Gut,2012,61(1):6-32.
[15] Öberg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2012,23Suppl 7:vii124-130. |
